The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 357:1056-1057 September 6, 2007 Number 10
NextNext

A Comparison of Three Initial Antiretroviral AIDS Regimens

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: Study A5095 by the AIDS Clinical Trials Group (ACTG) was a randomized, double-blind, placebo-controlled, comparative study of three antiretroviral regimens for the initial treatment of human immunodeficiency virus (HIV) infection. The three regimens were zidovudine, lamivudine, and abacavir (the triple-nucleoside regimen), the triple-nucleoside regimen plus efavirenz (the four-drug regimen), and zidovudine, lamivudine, and efavirenz (the three-drug, standard-of-care regimen). The study was designed to follow patients for 120 weeks after randomization. The primary study end point was the time to virologic failure, which was defined as a confirmed HIV RNA level of more than 200 copies per milliliter . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.